{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:50:34Z","timestamp":1779144634330,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T00:00:00Z","timestamp":1342483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1742-4690-9-57","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T15:41:50Z","timestamp":1342539710000},"source":"Crossref","is-referenced-by-count":13,"title":["Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal"],"prefix":"10.1186","volume":"9","author":[{"given":"Koen K A","family":"Van Rompay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin A","family":"Trott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartika","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia C","family":"LaBranche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Landucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lipscomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross P","family":"Tarara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don R","family":"Canfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald N","family":"Forthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,17]]},"reference":[{"key":"2889_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","unstructured":"Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008, 372: 293-299.","journal-title":"Lancet"},{"key":"2889_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1126\/science.332.6031.784","volume":"332","author":"J Cohen","year":"2011","unstructured":"Cohen J: The emerging race to cure HIV infections. Science. 2011, 332: 784-785. 10.1126\/science.332.6031.784. 787\u2013789","journal-title":"Science"},{"key":"2889_CR3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1126\/science.1165706","volume":"323","author":"DD Richman","year":"2009","unstructured":"Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ: The challenge of finding a cure for HIV infection. Science. 2009, 323: 1304-1307. 10.1126\/science.1165706.","journal-title":"Science"},{"key":"2889_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1126\/science.1191047","volume":"329","author":"D Trono","year":"2010","unstructured":"Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N: HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010, 329: 174-180. 10.1126\/science.1191047.","journal-title":"Science"},{"key":"2889_CR5","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1016\/j.vaccine.2011.07.043","volume":"29","author":"F Garcia","year":"2011","unstructured":"Garcia F, Routy JP: Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine. 2011, 29: 6454-6463. 10.1016\/j.vaccine.2011.07.043.","journal-title":"Vaccine"},{"key":"2889_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/QCO.0b013e3282f4069d","volume":"21","author":"NI Paton","year":"2008","unstructured":"Paton NI: Treatment interruption strategies: how great are the risks?. Curr Opin Infect Dis. 2008, 21: 25-30. 10.1097\/QCO.0b013e3282f4069d.","journal-title":"Curr Opin Infect Dis"},{"key":"2889_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/01.COH.0000232348.15909.c6","volume":"1","author":"B Autran","year":"2006","unstructured":"Autran B, Kinloch-de Loes S, Katlama C: Therapeutic immunization in HIV infection. Curr Opin HIV AIDS. 2006, 1: 323-329. 10.1097\/01.COH.0000232348.15909.c6.","journal-title":"Curr Opin HIV AIDS"},{"key":"2889_CR8","doi-asserted-by":"publisher","first-page":"e10555","DOI":"10.1371\/journal.pone.0010555","volume":"5","author":"ES Rosenberg","year":"2010","unstructured":"Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, et al: Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute\/early HIV-1 infection. PLoS One. 2010, 5: e10555-10.1371\/journal.pone.0010555.","journal-title":"PLoS One"},{"key":"2889_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2009.07.008","volume":"85","author":"KK Van Rompay","year":"2010","unstructured":"Van Rompay KK: Evaluation of antiretrovirals in animal models of HIV infection. Antivir Res. 2010, 85: 159-175. 10.1016\/j.antiviral.2009.07.008.","journal-title":"Antivir Res"},{"key":"2889_CR10","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1128\/JVI.78.10.5324-5337.2004","volume":"78","author":"KKA Van Rompay","year":"2004","unstructured":"Van Rompay KKA, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N: CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol. 2004, 78: 5324-5337. 10.1128\/JVI.78.10.5324-5337.2004.","journal-title":"J Virol"},{"key":"2889_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1742-4690-4-25","volume":"4","author":"KK Van Rompay","year":"2007","unstructured":"Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, Marthas ML, Pedersen NC, Bischofberger N, Heneine W, North TW: Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology. 2007, 4: 25-10.1186\/1742-4690-4-25.","journal-title":"Retrovirology"},{"key":"2889_CR12","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1128\/AAC.40.11.2586","volume":"40","author":"KKA Van Rompay","year":"1996","unstructured":"Van Rompay KKA, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischofberger N, Pedersen NC: 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother. 1996, 40: 2586-2591.","journal-title":"Antimicrob Agents Chemother"},{"key":"2889_CR13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/AAC.43.4.802","volume":"43","author":"KKA Van Rompay","year":"1999","unstructured":"Van Rompay KKA, Cherrington JM, Marthas ML, Lamy PD, Dailey PJ, Canfield DR, Tarara RP, Bischofberger N, Pedersen NC: 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother. 1999, 43: 802-812.","journal-title":"Antimicrob Agents Chemother"},{"key":"2889_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1128\/AAC.48.5.1469-1487.2004","volume":"48","author":"KKA Van Rompay","year":"2004","unstructured":"Van Rompay KKA, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, et al: Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004, 48: 1469-1487. 10.1128\/AAC.48.5.1469-1487.2004.","journal-title":"Antimicrob Agents Chemother"},{"key":"2889_CR15","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1128\/AAC.00350-08","volume":"52","author":"KK Van Rompay","year":"2008","unstructured":"Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, et al: Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008, 52: 3144-3160. 10.1128\/AAC.00350-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"2889_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1742-4690-3-97","volume":"3","author":"KJ Metzner","year":"2006","unstructured":"Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI: Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology. 2006, 3: 97-10.1186\/1742-4690-3-97.","journal-title":"Retrovirology"},{"key":"2889_CR17","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1128\/JVI.74.4.1767-1774.2000","volume":"74","author":"KKA Van Rompay","year":"2000","unstructured":"Van Rompay KKA, Miller MD, Marthas ML, Margot NA, Dailey PJ, Tarara RP, Canfield DR, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC: Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol. 2000, 74: 1767-1774. 10.1128\/JVI.74.4.1767-1774.2000.","journal-title":"J Virol"},{"key":"2889_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-0684.2006.00179.x","volume":"35","author":"JD Boyer","year":"2006","unstructured":"Boyer JD, Kumar S, Robinson T, Parkinson R, Wu L, Lewis M, Watkins DI, Weiner DB: Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response. J Med Primatol. 2006, 35: 202-209. 10.1111\/j.1600-0684.2006.00179.x.","journal-title":"J Med Primatol"},{"key":"2889_CR19","doi-asserted-by":"publisher","first-page":"8827","DOI":"10.1128\/JVI.00895-07","volume":"81","author":"JT Loffredo","year":"2007","unstructured":"Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, et al: Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol. 2007, 81: 8827-8832. 10.1128\/JVI.00895-07.","journal-title":"J Virol"},{"key":"2889_CR20","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1128\/JVI.80.10.5074-5077.2006","volume":"80","author":"LJ Yant","year":"2006","unstructured":"Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O'Connor DH, Carrington M, Watkins DI: The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol. 2006, 80: 5074-5077. 10.1128\/JVI.80.10.5074-5077.2006.","journal-title":"J Virol"},{"key":"2889_CR21","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1128\/JVI.77.4.2736-2740.2003","volume":"77","author":"BR Moth\u00e9","year":"2003","unstructured":"Moth\u00e9 BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, Allison DB, Watkins DI: Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol. 2003, 77: 2736-2740. 10.1128\/JVI.77.4.2736-2740.2003.","journal-title":"J Virol"},{"key":"2889_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1086\/496985","volume":"41","author":"S Sungkanuparph","year":"2005","unstructured":"Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG: Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005, 41: 1326-1332. 10.1086\/496985.","journal-title":"Clin Infect Dis"},{"key":"2889_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/00126334-200408010-00003","volume":"36","author":"KKA Van Rompay","year":"2004","unstructured":"Van Rompay KKA, Singh R, Brignolo L, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Bischofberger N, Marthas M: The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. JAIDS. 2004, 36: 900-914. 10.1097\/00126334-200408010-00003.","journal-title":"JAIDS"},{"key":"2889_CR24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006, 443: 350-354. 10.1038\/nature05115.","journal-title":"Nature"},{"key":"2889_CR25","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1084\/jem.20061800","volume":"203","author":"GJ Freeman","year":"2006","unstructured":"Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006, 203: 2223-2227. 10.1084\/jem.20061800.","journal-title":"J Exp Med"},{"key":"2889_CR26","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1128\/JVI.78.5.2434-2444.2004","volume":"78","author":"M Magierowska","year":"2004","unstructured":"Magierowska M, Bernardin F, Garg S, Staprans S, Miller MD, Van Rompay KKA, Delwart EL: Highly uneven distribution of PMPA selected SIV drug resistance genotypes in different anatomical sites of rhesus macaques. J Virol. 2004, 78: 2434-2444. 10.1128\/JVI.78.5.2434-2444.2004.","journal-title":"J Virol"},{"key":"2889_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jtbi.2009.06.011","volume":"260","author":"L Rong","year":"2009","unstructured":"Rong L, Perelson AS: Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol. 2009, 260: 308-331. 10.1016\/j.jtbi.2009.06.011.","journal-title":"J Theor Biol"},{"key":"2889_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood.V99.2.590","volume":"99","author":"F Villinger","year":"2002","unstructured":"Villinger F, Brice GT, Mayne AE, Bostik P, Mori K, June CH, Ansari AA: Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4+ T cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood. 2002, 99: 590-599. 10.1182\/blood.V99.2.590.","journal-title":"Blood"},{"key":"2889_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/415335a","volume":"415","author":"DH Barouch","year":"2002","unstructured":"Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyeri FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, et al: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002, 415: 335-339. 10.1038\/415335a.","journal-title":"Nature"},{"key":"2889_CR30","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1128\/JVI.77.5.3099-3118.2003","volume":"77","author":"K Abel","year":"2003","unstructured":"Abel K, Compton L, Rourke T, Montefiori D, Lu D, Rothaeusler K, Fritts L, Bost K, Miller CJ: Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol. 2003, 77: 3099-3118. 10.1128\/JVI.77.5.3099-3118.2003.","journal-title":"J Virol"},{"key":"2889_CR31","doi-asserted-by":"publisher","first-page":"15831","DOI":"10.1073\/pnas.0902628106","volume":"106","author":"M Rosati","year":"2009","unstructured":"Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, Patel V, von Gegerfelt AS, Montefiori DC, Venzon DJ, et al: DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A. 2009, 106: 15831-15836. 10.1073\/pnas.0902628106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2889_CR32","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1128\/AAC.01380-09","volume":"54","author":"PM Grant","year":"2010","unstructured":"Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR: Antiviral Activity of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase: An International Cohort Analysis. Antimicrob Agents Chemother. 2010, 54: 1520-1525. 10.1128\/AAC.01380-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"2889_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0b013e3280187533","volume":"21","author":"BJ Chappell","year":"2007","unstructured":"Chappell BJ, Margot NA, Miller MD: Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. AIDS. 2007, 21: 761-763. 10.1097\/QAD.0b013e3280187533.","journal-title":"AIDS"},{"key":"2889_CR34","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/00126334-200411010-00002","volume":"37","author":"DJ McColl","year":"2004","unstructured":"McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD: Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2004, 37: 1340-1350. 10.1097\/00126334-200411010-00002.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2889_CR35","first-page":"195","volume":"9","author":"NK Saksena","year":"2007","unstructured":"Saksena NK, Rodes B, Wang B, Soriano V: Elite HIV controllers: myth or reality?. AIDS Rev. 2007, 9: 195-207.","journal-title":"AIDS Rev"},{"key":"2889_CR36","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.1128\/JVI.02746-05","volume":"80","author":"DN Forthal","year":"2006","unstructured":"Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K: Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006, 80: 9217-9225. 10.1128\/JVI.02746-05.","journal-title":"J Virol"},{"key":"2889_CR37","doi-asserted-by":"publisher","first-page":"11181","DOI":"10.1128\/JVI.01433-08","volume":"82","author":"M Genesca","year":"2008","unstructured":"Genesca M, Skinner PJ, Hong JJ, Li J, Lu D, McChesney MB, Miller CJ: With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol. 2008, 82: 11181-11196. 10.1128\/JVI.01433-08.","journal-title":"J Virol"},{"key":"2889_CR38","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1128\/JVI.02308-05","volume":"80","author":"KKA Van Rompay","year":"2006","unstructured":"Van Rompay KKA, Singh RP, Heneine W, Johnson JA, Montefiori DC, Bischofberger N, Marthas ML: Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol. 2006, 80: 6399-6410. 10.1128\/JVI.02308-05.","journal-title":"J Virol"},{"key":"2889_CR39","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1128\/JVI.73.4.2947-2955.1999","volume":"73","author":"KKA Van Rompay","year":"1999","unstructured":"Van Rompay KKA, Dailey PJ, Tarara RP, Canfield DR, Aguirre NL, Cherrington JM, Lamy PD, Bischofberger N, Pedersen NC, Marthas ML: Early short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol. 1999, 73: 2947-2955.","journal-title":"J Virol"},{"key":"2889_CR40","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/80481","volume":"6","author":"Z Hel","year":"2000","unstructured":"Hel Z, Venzon D, Poudyal M, Tsai W-P, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins DW, et al: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med. 2000, 6: 1140-1146. 10.1038\/80481.","journal-title":"Nat Med"},{"key":"2889_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.virol.2005.12.008","volume":"348","author":"DH Fuller","year":"2006","unstructured":"Fuller DH, Rajakumar PA, Wu MS, McMahon CW, Shipley T, Fuller JT, Bazmi A, Trichel AM, Allen TM, Mothe B, et al: DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology. 2006, 348: 200-215. 10.1016\/j.virol.2005.12.008.","journal-title":"Virology"},{"key":"2889_CR42","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1128\/JVI.74.4.1704-1711.2000","volume":"74","author":"B Rosenwirth","year":"2000","unstructured":"Rosenwirth B, ten Haaft P, Bogers WMJM, Nieuwenhuis IG, Niphuis H, Kuhn E-M, Bischofberger N, Heeney JL, \u00dcberla K: Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol. 2000, 74: 1704-1711. 10.1128\/JVI.74.4.1704-1711.2000.","journal-title":"J Virol"},{"key":"2889_CR43","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1128\/JVI.79.12.7349-7354.2005","volume":"79","author":"TW North","year":"2005","unstructured":"North TW, Van Rompay KKA, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF: Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol. 2005, 79: 7349-7354. 10.1128\/JVI.79.12.7349-7354.2005.","journal-title":"J Virol"},{"key":"2889_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1600-0684.1999.tb00270.x","volume":"28","author":"B Rosenwirth","year":"1999","unstructured":"Rosenwirth B, Bogers WM, Nieuwenhuis IG, Haaft PT, Niphuis H, Kuhn EM, Bischofberger N, Erfle V, Sutter G, Berglund P, et al: An anti-HIV strategy combining chemotherapy and therapeutic vaccination. J Med Primatol. 1999, 28: 195-205. 10.1111\/j.1600-0684.1999.tb00270.x.","journal-title":"J Med Primatol"},{"key":"2889_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1006\/viro.2000.0720","volume":"279","author":"M Spring","year":"2001","unstructured":"Spring M, Stahl-Hennig C, Stolte N, Bischofberger N, Heeney J, ten Haaft P, Tenner-R\u00e0cz K, R\u00e0cz P, Lorenzen D, Hunsmann G, Dittmer U: Enhanced cellular immune responses and reduced CD8+ lymphocytes apoptosis in acutely SIV-infected rhesus macaques after short-term antiretroviral treatment. Virology. 2001, 279: 221-231. 10.1006\/viro.2000.0720.","journal-title":"Virology"},{"key":"2889_CR46","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1006\/viro.2000.0609","volume":"277","author":"MS Smith","year":"2000","unstructured":"Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, Page A, Wang C, Li Z, Adany I, et al: Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment of SHIVKU2 infection of rhesus macaques. Virology. 2000, 277: 306-315. 10.1006\/viro.2000.0609.","journal-title":"Virology"},{"key":"2889_CR47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.virol.2006.06.025","volume":"354","author":"R Taber","year":"2006","unstructured":"Taber R, Rajakumar PA, Fuller DH, Trichel AM, Dowling P, Meleason D, Amedee A, Murphey-Corb M: Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. Virology. 2006, 354: 116-131. 10.1016\/j.virol.2006.06.025.","journal-title":"Virology"},{"key":"2889_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/aid.1997.13.707","volume":"13","author":"C-C Tsai","year":"1997","unstructured":"Tsai C-C, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ: Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection. AIDS Res Hum Retrovir. 1997, 13: 707-712. 10.1089\/aid.1997.13.707.","journal-title":"AIDS Res Hum Retrovir"},{"key":"2889_CR49","first-page":"5347","volume":"169","author":"E Tryniszewska","year":"2002","unstructured":"Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, et al: Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. JI. 2002, 169: 5347-5357.","journal-title":"JI"},{"key":"2889_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0684.2006.00190.x","volume":"36","author":"K Uberla","year":"2007","unstructured":"Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V: Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. J Med Primatol. 2007, 36: 2-9. 10.1111\/j.1600-0684.2006.00190.x.","journal-title":"J Med Primatol"},{"key":"2889_CR51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/QAI.0b013e3181b880f3","volume":"52","author":"P Vagenas","year":"2009","unstructured":"Vagenas P, Williams VG, Piatak M, Bess JW, Lifson JD, Blanchard JL, Gettie A, Robbiani M: Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr. 2009, 52: 433-442. 10.1097\/QAI.0b013e3181b880f3.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2889_CR52","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1089\/aid.2008.0055","volume":"24","author":"J Zur Megede","year":"2008","unstructured":"Zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, et al: A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retrovir. 2008, 24: 1103-1116. 10.1089\/aid.2008.0055.","journal-title":"AIDS Res Hum Retrovir"},{"key":"2889_CR53","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1128\/JVI.02522-08","volume":"83","author":"M Kubo","year":"2009","unstructured":"Kubo M, Nishimura Y, Shingai M, Lee W, Brenchley J, Lafont B, Buckler-White A, Igarashi T, Martin MA: Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J Virol. 2009, 83: 7099-7108. 10.1128\/JVI.02522-08.","journal-title":"J Virol"},{"key":"2889_CR54","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.1128\/JVI.00472-06","volume":"80","author":"B Cervasi","year":"2006","unstructured":"Cervasi B, Paiardini M, Serafini S, Fraternale A, Menotta M, Engram J, Lawson B, Staprans SI, Piedimonte G, Perno CF, et al: Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy. J Virol. 2006, 80: 10335-10345. 10.1128\/JVI.00472-06.","journal-title":"J Virol"},{"key":"2889_CR55","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1126\/science.280.5371.1866","volume":"280","author":"DD Ho","year":"1998","unstructured":"Ho DD: Toward HIV eradication or remission: the tasks ahead. Science. 1998, 280: 1866-1867. 10.1126\/science.280.5371.1866.","journal-title":"Science"},{"key":"2889_CR56","doi-asserted-by":"publisher","first-page":"F59","DOI":"10.1097\/00002030-199905280-00001","volume":"13","author":"PR Harrigan","year":"1999","unstructured":"Harrigan PR, Whaley M, Montaner JSG: Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999, 13: F59-F62. 10.1097\/00002030-199905280-00001.","journal-title":"AIDS"},{"key":"2889_CR57","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/44755","volume":"401","author":"TW Chun","year":"1999","unstructured":"Chun TW, Davey RTJ, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature. 1999, 401: 874-875. 10.1038\/44755.","journal-title":"Nature"},{"key":"2889_CR58","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/00126334-200411010-00003","volume":"37","author":"DJ Skiest","year":"2004","unstructured":"Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, Hardy RD: It Is Safe to Stop Antiretroviral Therapy in Patients With Preantiretroviral CD4 Cell Counts >250 cells\/microL. J Acquir Immune Defic Syndr. 2004, 37: 1351-1357. 10.1097\/00126334-200411010-00003.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2889_CR59","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1097\/QAD.0b013e32833b61ba","volume":"24","author":"L Hocqueloux","year":"2010","unstructured":"Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010, 24: 1598-1601. 10.1097\/QAD.0b013e32833b61ba.","journal-title":"AIDS"},{"key":"2889_CR60","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1086\/380098","volume":"189","author":"SG Deeks","year":"2004","unstructured":"Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, Hagos E, Wrin T, Petropoulos CJ, Bredt B, McCune JM: Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis. 2004, 189: 312-321. 10.1086\/380098.","journal-title":"J Infect Dis"},{"key":"2889_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00002030-200501030-00003","volume":"19","author":"N Alatrakchi","year":"2005","unstructured":"Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin A, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C: Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS. 2005, 19: 25-33. 10.1097\/00002030-200501030-00003.","journal-title":"AIDS"},{"key":"2889_CR62","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1086\/430709","volume":"41","author":"TB Campbell","year":"2005","unstructured":"Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR: Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005, 41: 236-242. 10.1086\/430709.","journal-title":"Clin Infect Dis"},{"key":"2889_CR63","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1097\/00126334-200412150-00009","volume":"37","author":"JJ Eron","year":"2004","unstructured":"Eron JJ, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR, St Clair MH, Johnson VA: Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr. 2004, 37: 1581-1583. 10.1097\/00126334-200412150-00009.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2889_CR64","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1086\/496892","volume":"192","author":"SG Deeks","year":"2005","unstructured":"Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN: Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005, 192: 1537-1544. 10.1086\/496892.","journal-title":"J Infect Dis"},{"key":"2889_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.antiviral.2004.04.002","volume":"63","author":"KKA Van Rompay","year":"2004","unstructured":"Van Rompay KKA, Marthas ML, Bischofberger N: Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion. Antivir Res. 2004, 63: 133-138. 10.1016\/j.antiviral.2004.04.002.","journal-title":"Antivir Res"},{"key":"2889_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11373-006-9116-4","volume":"14","author":"P Potmesil","year":"2007","unstructured":"Potmesil P, Holy A, Kmonickova E, Krizkova J, Zidek Z: Acyclic nucleoside phosphonate antivirals activate gene expression of monocyte chemotactic protein 1 and 3. J Biomed Sci. 2007, 14: 59-66. 10.1007\/s11373-006-9116-4.","journal-title":"J Biomed Sci"},{"key":"2889_CR67","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"1996","unstructured":"National Research Council: Guide for the care and use of laboratory animals. 1996, National Academy Press, Washington, D. C."},{"key":"2889_CR68","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1128\/JVI.77.10.5621-5631.2003","volume":"77","author":"BL Shacklett","year":"2003","unstructured":"Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF: Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol. 2003, 77: 5621-5631. 10.1128\/JVI.77.10.5621-5631.2003.","journal-title":"J Virol"},{"key":"2889_CR69","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0684.2005.00128.x","volume":"34","author":"AN Cline","year":"2005","unstructured":"Cline AN, Bess JW, Piatak M, Lifson JD: Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol. 2005, 34: 303-312. 10.1111\/j.1600-0684.2005.00128.x.","journal-title":"J Med Primatol"},{"key":"2889_CR70","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2353\/ajpath.2008.070967","volume":"172","author":"S Venneti","year":"2008","unstructured":"Venneti S, Bonneh-Barkay D, Lopresti BJ, Bissel SJ, Wang G, Mathis CA, Piatak M, Lifson JD, Nyaundi JO, Murphey-Corb M, Wiley CA: Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. Am J Pathol. 2008, 172: 1603-1616. 10.2353\/ajpath.2008.070967.","journal-title":"Am J Pathol"},{"key":"2889_CR71","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1089\/aid.2006.22.912","volume":"22","author":"JA Johnson","year":"2006","unstructured":"Johnson JA, Van Rompay KKA, Delwart E, Heneine W: A sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase. AIDS Res Hum Retrovir. 2006, 22: 912-916. 10.1089\/aid.2006.22.912.","journal-title":"AIDS Res Hum Retrovir"},{"key":"2889_CR72","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00251-007-0233-7","volume":"59","author":"M Kaizu","year":"2007","unstructured":"Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, Watkins DI, Rehrauer WM: Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics. 2007, 59: 693-703. 10.1007\/s00251-007-0233-7.","journal-title":"Immunogenetics"},{"key":"2889_CR73","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.vaccine.2009.11.061","volume":"28","author":"KK Van Rompay","year":"2010","unstructured":"Van Rompay KK, Abel K, Earl P, Kozlowski PA, Easlick J, Moore J, Buonocore-Buzzelli L, Schmidt KA, Wilson RL, Simon I, et al: Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine. 2010, 28: 1481-1492. 10.1016\/j.vaccine.2009.11.061.","journal-title":"Vaccine"},{"key":"2889_CR74","first-page":"12.11.11","volume-title":"Current Protocols in Immunology","author":"DC Montefiori","year":"2004","unstructured":"Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current Protocols in Immunology. Edited by: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R. 2004, John Wiley & Sons, 12.11.11-12.11.15."},{"key":"2889_CR75","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","volume":"79","author":"M Li","year":"2005","unstructured":"Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005, 79: 10108-10125. 10.1128\/JVI.79.16.10108-10125.2005.","journal-title":"J Virol"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-4690-9-57.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1742-4690-9-57\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-4690-9-57.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T23:27:36Z","timestamp":1594423656000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/1742-4690-9-57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,17]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2889"],"URL":"https:\/\/doi.org\/10.1186\/1742-4690-9-57","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,17]]},"article-number":"57"}}